Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Mirzaei, R; Goodarzi, P; Asadi, M; Soltani, A; Aljanabi, HAA; Jeda, AS; Dashtbin, S; Jalalifar, S; Mohammadzadeh, R; Teimoori, A; Tari, K; Salari, M; Ghiasvand, S; Kazemi, S; Yousefimashouf, R; Keyvani, H; Karampoor, S.
Bacterial co-infections with SARS-CoV-2.
IUBMB Life. 2020; 72(10): 2097-2111.
Doi: 10.1002/iub.2356
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Mohammadzadeh Rokhsareh
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The pandemic coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has affected millions of people worldwide. To date, there are no proven effective therapies for this virus. Efforts made to develop antiviral strategies for the treatment of COVID-19 are underway. Respiratory viral infections, such as influenza, predispose patients to co-infections and these lead to increased disease severity and mortality. Numerous types of antibiotics such as azithromycin have been employed for the prevention and treatment of bacterial co-infection and secondary bacterial infections in patients with a viral respiratory infection (e.g., SARS-CoV-2). Although antibiotics do not directly affect SARS-CoV-2, viral respiratory infections often result in bacterial pneumonia. It is possible that some patients die from bacterial co-infection rather than virus itself. To date, a considerable number of bacterial strains have been resistant to various antibiotics such as azithromycin, and the overuse could render those or other antibiotics even less effective. Therefore, bacterial co-infection and secondary bacterial infection are considered critical risk factors for the severity and mortality rates of COVID-19. Also, the antibiotic-resistant as a result of overusing must be considered. In this review, we will summarize the bacterial co-infection and secondary bacterial infection in some featured respiratory viral infections, especially COVID-19.
- Find related publications in this database (using NLM MeSH Indexing)
- Acinetobacter baumannii - drug effects, pathogenicity
- Anti-Bacterial Agents - therapeutic use
- Antiviral Agents - therapeutic use
- Bacterial Infections - drug therapy, epidemiology, microbiology, virology
- COVID-19 - drug therapy, epidemiology, microbiology, virology
- Coinfection - administration & dosage
- Haemophilus influenzae - drug effects, pathogenicity
- Host-Pathogen Interactions - immunology
- Humans - administration & dosage
- Immunity, Innate - drug effects
- Klebsiella pneumoniae - drug effects, pathogenicity
- Legionella pneumophila - drug effects, pathogenicity
- Methicillin-Resistant Staphylococcus aureus - drug effects, pathogenicity
- Pandemics - administration & dosage
- Pneumonia, Bacterial - drug therapy, epidemiology, microbiology, virology
- Pseudomonas aeruginosa - drug effects, pathogenicity
- Respiratory System - drug effects, microbiology, pathology, virology
- SARS-CoV-2 - drug effects, pathogenicity
- Streptococcus pneumoniae - drug effects, pathogenicity
- Streptococcus pyogenes - drug effects, pathogenicity
- Find related publications in this database (Keywords)
- antibiotic
- bacterial co-infection
- COVID-19
- SARS-CoV-2
- viral infection